APA

Nomura M., Oze I., Abe T., Komori A., Narita Y., Masuishi T., Taniguchi H., Kadowaki S., Ura T., Andoh M., Kawai R., Uemura N., Ishihara M., Tanaka T., Tajika M., Niwa Y., Muro K. & Muto M. (20151013). Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. : Cancer chemotherapy and pharmacology.

Chicago

Nomura Motoo, Oze Isao, Abe Tetsuya, Komori Azusa, Narita Yukiya, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Ura Takashi, Andoh Masashi, Kawai Ryosuke, Uemura Norihisa, Ishihara Makoto, Tanaka Tsutomu, Tajika Masahiro, Niwa Yasumasa, Muro Kei and Muto Manabu. 20151013. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. : Cancer chemotherapy and pharmacology.

Harvard

Nomura M., Oze I., Abe T., Komori A., Narita Y., Masuishi T., Taniguchi H., Kadowaki S., Ura T., Andoh M., Kawai R., Uemura N., Ishihara M., Tanaka T., Tajika M., Niwa Y., Muro K. and Muto M. (20151013). Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. : Cancer chemotherapy and pharmacology.

MLA

Nomura Motoo, Oze Isao, Abe Tetsuya, Komori Azusa, Narita Yukiya, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Ura Takashi, Andoh Masashi, Kawai Ryosuke, Uemura Norihisa, Ishihara Makoto, Tanaka Tsutomu, Tajika Masahiro, Niwa Yasumasa, Muro Kei and Muto Manabu. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. : Cancer chemotherapy and pharmacology. 20151013.